Q-omics provides the consensus-scored KANK2 profile across patient tissues and cancer cell-line models. KANK2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, KANK2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, KANK2 protein abundance shows 36,201 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, BLCA, and LSCC as cancer lineages where KANK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KANK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KANK2 survival associations across molecular data types. KANK2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KANK2 RNA expression–survival associations across cancer types. High KANK2 expression shows unfavorable associations in KICH, LUSC and LGG, but favorable associations in UCS, HNSC and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for KANK2 RNA expression.
This table summarizes KANK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KANK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KANK2 shows lower tumor expression in BLCA, LUSC, LUAD and COAD and higher tumor expression in LIHC and HNSC. The BLCA box plot shows higher KANK2 RNA expression in normal versus tumor tissue (log2 FC = −3.574, t-test p < 0.001).
This table shows molecular features associated with KANK2 in patient tissues and cancer cell lines. In patient samples, KANK2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KANK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
